Maruho Licenses Cancer Stomatitis Treatment from NCC

October 2, 2018
The National Cancer Center Japan (NCC) and Maruho said on October 1 that they have entered into a license agreement for exclusive worldwide rights to develop, manufacture, and commercialize NCC’s novel analgesic for intractable stomatitis in cancer treatment and a...read more